Insulin-Binding Peptide Probes Provide a Novel Strategy for Pancreatic β-Cell Imaging

Author(s):  
Maria Eriksson ◽  
Sara A. Litwak ◽  
Yan Yun ◽  
William J. Stanley ◽  
Peter Thorn ◽  
...  
2015 ◽  
Vol 18 (1) ◽  
pp. 6-15 ◽  
Author(s):  
D. Laurent ◽  
L. Vinet ◽  
S. Lamprianou ◽  
M. Daval ◽  
G. Filhoulaud ◽  
...  

2018 ◽  
Vol 26 (2) ◽  
pp. 463-469 ◽  
Author(s):  
Hiroyuki Kimura ◽  
Yu Ogawa ◽  
Hiroyuki Fujimoto ◽  
Eri Mukai ◽  
Hidekazu Kawashima ◽  
...  

Author(s):  
Bikash Manandhar ◽  
William Silvers ◽  
Amit Kumar ◽  
Su-Tang Lo ◽  
Xiankai Sun ◽  
...  

2015 ◽  
Vol 18 (1) ◽  
pp. 90-98 ◽  
Author(s):  
Nilantha Bandara ◽  
Alex Zheleznyak ◽  
Kaavya Cherukuri ◽  
David A. Griffith ◽  
Chris Limberakis ◽  
...  

2009 ◽  
Vol 389 (3) ◽  
pp. 523-526 ◽  
Author(s):  
Eri Mukai ◽  
Kentaro Toyoda ◽  
Hiroyuki Kimura ◽  
Hidekazu Kawashima ◽  
Hiroyuki Fujimoto ◽  
...  

2019 ◽  
Vol 133 (22) ◽  
pp. 2317-2327 ◽  
Author(s):  
Nicolás Gómez-Banoy ◽  
James C. Lo

Abstract The growing prevalence of obesity and its related metabolic diseases, mainly Type 2 diabetes (T2D), has increased the interest in adipose tissue (AT) and its role as a principal metabolic orchestrator. Two decades of research have now shown that ATs act as an endocrine organ, secreting soluble factors termed adipocytokines or adipokines. These adipokines play crucial roles in whole-body metabolism with different mechanisms of action largely dependent on the tissue or cell type they are acting on. The pancreatic β cell, a key regulator of glucose metabolism due to its ability to produce and secrete insulin, has been identified as a target for several adipokines. This review will focus on how adipokines affect pancreatic β cell function and their impact on pancreatic β cell survival in disease contexts such as diabetes. Initially, the “classic” adipokines will be discussed, followed by novel secreted adipocyte-specific factors that show therapeutic promise in regulating the adipose–pancreatic β cell axis.


2011 ◽  
pp. 5-10
Author(s):  
Huu Dang Tran

The incretins are peptide hormones secreted from the gut in response to food. They increase the secretion of insulin. The incretin response is reduced in patients with type 2 diabetes so drugs acting on incretins may improve glycaemic control. Incretins are metabolised by dipeptidyl peptidase, so selectively inhibiting this enzyme increases the concentration of circulating incretins. A similar effect results from giving an incretin analogue that cannot be cleaved by dipeptidyl peptidase. Studies have identified other actions including improvement in pancreatic β cell glucose sensitivity and, in animal studies, promotion of pancreatic β cell proliferation and reduction in β cell apoptosis.


Sign in / Sign up

Export Citation Format

Share Document